John M Essigmann Selected Research

Aflatoxin B1 (Aflatoxin B)

11/2017	Mutational spectra of aflatoxin B1 in vivo establish biomarkers of exposure for human hepatocellular carcinoma.
1/2017	Early detection of the aflatoxin B1 mutational fingerprint: A diagnostic tool for liver cancer.
3/2015	Prenatal exposure of mice to the human liver carcinogen aflatoxin B1 reveals a critical window of susceptibility to genetic change.
1/2015	Sulforaphane, a cancer chemopreventive agent, induces pathways associated with membrane biosynthesis in response to tissue damage by aflatoxin B1.
8/2012	A single neonatal exposure to aflatoxin b1 induces prolonged genetic damage in two loci of mouse liver.
8/2012	AFB(1) -induced mutagenesis of the gpt gene in AS52 cells.
7/2011	Aflatoxin B1-DNA adduct formation and mutagenicity in livers of neonatal male and female B6C3F1 mice.
5/2002	The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John M Essigmann Research Topics

Disease

16	Neoplasms (Cancer) 01/2021 - 01/2002
6	Hepatocellular Carcinoma (Hepatoma) 11/2017 - 05/2002
4	Liver Neoplasms (Liver Cancer) 01/2017 - 05/2002
3	Inflammation (Inflammations) 01/2019 - 04/2007
2	Infections 01/2019 - 01/2002
2	Prostatic Neoplasms (Prostate Cancer) 09/2011 - 07/2005
2	Carcinogenesis 07/2011 - 05/2011
1	Poisoning 02/2021
1	Hepatitis B 11/2017
1	Inborn Genetic Diseases (Disease, Hereditary) 03/2015
1	Breast Neoplasms (Breast Cancer) 03/2002

Drug/Important Bio-Agent (IBA)

8	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2002
8	Aflatoxin B1 (Aflatoxin B)IBA 11/2017 - 05/2002
5	AflatoxinsIBA 01/2017 - 05/2002
4	DNA AdductsIBA 01/2017 - 07/2005
4	MutagensIBA 03/2015 - 03/2002
3	A-Form DNA (A-DNA)IBA 09/2011 - 07/2005
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2005
2	Biomarkers (Surrogate Marker)IBA 11/2017 - 08/2015
2	CarcinogensIBA 01/2017 - 03/2015
2	Androgen Receptors (Androgen Receptor)IBA 09/2011 - 07/2005
2	Antineoplastic Agents (Antineoplastics)IBA 09/2011 - 01/2007
2	LigandsIBA 09/2011 - 07/2005
2	GuanineIBA 05/2011 - 04/2007
2	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 12/2009 - 01/2002
2	Estrogen ReceptorsIBA 02/2009 - 03/2002
1	AntioxidantsIBA 02/2021
1	NitrosaminesIBA 01/2021
1	Temozolomide (Temodar)FDA LinkGeneric 01/2020
1	MethyltransferasesIBA 01/2020
1	Interleukin-22 (IL-22)IBA 01/2019
1	colibactinIBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	Interleukin-10 (Interleukin 10)IBA 01/2019
1	cytolethal distending toxinIBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	EnzymesIBA 01/2017
1	alpha-hydroxyglutarateIBA 01/2017
1	Hypochlorous Acid (Hypochlorite)IBA 08/2015
1	5-chlorocytosineIBA 08/2015
1	sulforaphaneIBA 01/2015
1	Aniline MustardIBA 09/2011
1	PlatinumIBA 02/2009
1	DNA-(Apurinic or Apyrimidinic Site) Lyase (AP Endonuclease)IBA 01/2009
1	Oxygen (Dioxygen)IBA 04/2007
1	NitrogenIBA 04/2007
1	Carmustine (FIVB)FDA Link 01/2007
1	Adenine FDA LinkGeneric 01/2007
1	1,N(6)-ethanoadenineIBA 01/2007
1	AlkB EnzymesIBA 10/2005
1	Codon (Codons)IBA 05/2002
1	4,6-diamino-5-N-formamidopyrimidine (FAPy)IBA 05/2002
1	Cisplatin (Platino)FDA LinkGeneric 01/2002
1	Pharmaceutical PreparationsIBA 01/2002

Therapy/Procedure

1	Therapeutics 01/2020
1	Drug Therapy (Chemotherapy) 01/2020